Short summary

This study builds on the findings of a danish study that has shown an increased incidence of squamous cell carcinoma in patients who are either or have been in a hydrochlorothiazide treatment. The purpose of the study is to quantify the concentration of hydrochlorothiazide and bendroflumethiazide in epidermis and dermis 

Rationale

Hydrochlorothiazide is a frequently used antihypertensiva. It has photosensitizing properties, and a danish study indicate that use of hydrochlorothiazide is associated with increased risk of squamous cell carcinoma. Bendroflumethiazide is a similar thiazide, but unlike hydrochlorothiazide, it has not shown potential carcinogenicity despite having photosensitizing properties. These results lead to the hypothesis that hydrochlorothiazide distributes differently in the skin and reaches epidermis. The purpose of this project is to investigate the distribution of hydrochlorothiazide in the skin relative to the distribution of bendroflumethiazide.

Description of the cohort

Men and women in treatment with hydrochlorothiazide or bendroflumethiazide for min. 1 year

Data and biological material

Blood, skin biopsy and hair.

Collaborating researchers and departments

Clinical Pharmacology, Institute of Public Health, University of Southern Denmark

• Sidsel Arnspang Pedersen, MD, PhD

Publications associated with the project

Pedersen SA et al. “Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark”